Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease

  • Sanz, Pascual
  • Serratosa, José Maria
  • Sánchez, Marina P.
17 páginas, 2 figuras, Metformin is a drug in the family of biguanide compounds that is widely used in the treatment of type 2 diabetes (T2D). Interestingly, the therapeutic potential of metformin expands its prescribed use as an anti-diabetic drug. In this sense, it has been described that metformin administration has beneficial effects on different neurological conditions. In this work, we review the beneficial effects of this drug as a neuroprotective agent in different neurological diseases, with a special focus on epileptic disorders and Lafora disease, a particular type of progressive myoclonus epilepsy. In addition, we review the different proposed mechanisms of action of metformin to understand its function at the neurological level., This work was supported by grants from the Spanish Ministry of Science and Innovation –SAF2017-83151-R to P.S. and Rti2018-095784b-100 SAF to M.P.S. and J.M.S.—and a grant from the National Institutes of Health (P01 NS097197), which established the Lafora Epilepsy Cure Initiative (LECI), to P.S., J.M.S. and M.P.S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An empirical pipeline for personalized diagnosis of Lafora disease mutations

  • Brewer, M. Kathryn
  • Machio-Castello, Maria
  • Viana, Rosa
  • Wayne, Jeremiah L.
  • Kuchtová, Andrea
  • Simmons, Zoe R.
  • Sternbach, Sarah
  • Li, Sheng
  • García-Gimeno, María Adelaida
  • Serratosa, José M.
  • Sanz, Pascual
  • Vander Kooi, Craig W.
  • Gentry, Matthew S.
22 páginas, 6 figuras, 2 tablas. Contiene material suplementario, Lafora disease (LD) is a fatal childhood dementia characterized by progressive myoclonic epilepsy manifesting in the teenage years, rapid neurological decline, and death typically within ten years of onset. Mutations in either EPM2A, encoding the glycogen phosphatase laforin, or EPM2B, encoding the E3 ligase malin, cause LD. Whole exome sequencing has revealed many EPM2A variants associated with late-onset or slower disease progression. We established an empirical pipeline for characterizing the functional consequences of laforin missense mutations in vitro using complementary biochemical approaches. Analysis of 26 mutations revealed distinct functional classes associated with different outcomes that were supported by clinical cases. For example, F321C and G279C mutations have attenuated functional defects and are associated with slow progression. This pipeline enabled rapid characterization and classification of newly identified EPM2A mutations, providing clinicians and researchers genetic information to guide treatment of LD patients., This work was supported by the National Institutes of Health (P01 NS097197 to M.S.G., J.M.S. and P.S., R35 NS116824 to M.S.G., and F31 NS093892 to M.K.B), National Science Foundation (DBI2018007 and MCB1817414 to M.S.G.), and Epilepsy Foundation New Therapy Commercialization Grant to M.S.G. M.K.B. received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (No. 754510M). This project also received funding from the Spanish Ministry of Science and Innovation (SAF2017-83151-R to P.S. and RTI2018-095784b-100SAF to J.M.S)., Peer reviewed